TrumpRx Expands: AbbVie's Humira at 86% Discount and Genentech's Xofluza Join Platform

Event Analysis

According to CBS News (exclusive), AbbVie's Humira and Genentech's Xofluza have been added to the TrumpRx direct-to-consumer drug platform, with sales beginning as early as this Monday. Humira — one of the world's best-selling biologics — will be available at approximately $950, down from a list price exceeding $6,900, representing an ~86% discount. Genentech's flu treatment Xofluza drops to $50 from $168, a ~70% reduction. This brings TrumpRx to 61+ drugs across 11 companies, up from 40 in February.

The deals carry significant strategic concessions beyond pricing. As reported by Pharmaceutical Technology, AbbVie committed to a $100 billion U.S. investment in R&D and domestic manufacturing, while securing tariff exemptions and Medicaid price adjustments. Genentech similarly agreed to Medicaid access at foreign-equivalent prices and expansion of its North Carolina manufacturing facility. These aren't simple price cuts — they're structured agreements tying pharma cooperation to trade and fiscal policy.

What distinguishes this from prior drug pricing initiatives is the scale and speed of industry compliance. The Trump administration's "most-favored-nation" pricing framework — which anchors U.S. drug prices to the lowest prices paid by other countries — is rapidly being adopted voluntarily by major players ahead of potential Congressional codification through the proposed "Great Healthcare Plan." This signals a fundamental shift in how big pharma navigates U.S. policy risk. For the broader 2026 Stocks Market Outlook, this trend has direct implications for healthcare sector valuations and margin compression narratives.

What This Means for Traders

AbbVie (ABBV) is trading at $206.63, down 1.04% over the past 24 hours with an intraday range of $205.31–$209.00, per live market data. The modest pullback likely reflects near-term revenue pressure from deep discounts on Humira — already facing biosimilar competition — rather than a rejection of the broader deal. Notably, RBC has initiated coverage with an Outperform rating and a $260 price target, citing AbbVie's immunology pipeline strength as a longer-term offset.

For sector traders, the read-across to peers is mixed. Companies like Pfizer, Inc., Merck & Co., Inc., Eli Lilly and Company, and Johnson & Johnson face a binary choice: join TrumpRx on negotiated terms or risk political and regulatory exposure. Amgen Inc. is already reportedly expanding Enbrel and Otezla on the platform. The sector-wide implication is margin compression offset by tariff relief and volume gains — a net-neutral to modest-negative for large-cap pharma earnings unless manufacturing investments generate offsetting tax and operational benefits.

On the macro side, lower drug prices directly reduce healthcare CPI components, which could modestly support rate-cut narratives and benefit broader indices including the Dow Jones Industrial Average Index. Volatility for ABBV specifically warrants monitoring around the Monday sales launch — confirmation of consumer uptake could serve as a short-term catalyst to close the gap toward $209 resistance.

Trade AbbVie Inc. on CoinUnited.io

Trade ABBV with up to 1000xx leverage → | Create Free Account